TNF Inhibitor denied for failing step therapy by Florida Blue?

Florida Blue uses Prime Therapeutics or CVS Caremark depending on plan line. Step therapy through preferred biosimilar.

FL Statute 627.42393 limits step therapy when prior failure documented. Demand peer-to-peer review. Cite continuity-of-care for stable patients.

## Why Florida Blue Requires Step Therapy Before a TNF Inhibitor

Step therapy — sometimes called "fail-first" — is a coverage protocol in which an insurer requires a patient to try and demonstrate an inadequate response to one or more preferred (usually lower-cost) drugs before approving a higher-tier biologic such as a TNF inhibitor. For immune-mediated inflammatory conditions, this typically means documenting a trial with conventional disease-modifying agents or other first-line therapies before biologic coverage is approved.

Florida Blue's step-therapy protocol is grounded in its medical policy for the relevant condition, and the exact sequence required depends on the diagnosis. Step therapy is one of the most common reasons TNF inhibitor claims are denied at the prior-authorization stage.

## Why This Denial Is Often Appealable

Florida Blue and other insurers must comply with Florida's step-therapy override law (Florida Statute §627.42397), which requires insurers to grant exceptions when: (a) the required step-therapy drug is contraindicated or likely to cause harm; (b) the patient previously tried and failed the required drug; (c) the patient is clinically stable on the requested drug; or (d) a step-therapy override is otherwise clinically appropriate. Federal parity and medical-necessity principles provide additional grounds. A well-documented history of prior treatment failures is often sufficient to obtain the exception.

## Your Federal Appeal Rights

• Internal appeal: Submit your appeal within the timeframe in your denial notice. Pre-service non-urgent appeals must be decided within 30 days; post-service within 60 days.
• External review (ACA §2719): If the internal appeal is denied, you may request binding external review by an IRO within approximately four months of the final denial letter.
• Expedited review: Where delay would jeopardize health, request expedited processing (typically decided within 72 hours).
• ERISA §503: Employer-plan members have the right to a full-and-fair review and access to all documents used in the decision.

## Documentation to Gather

1. Prior-therapy history with dates and outcomes — a comprehensive, dated list of every previously tried medication (name, start date, stop date, reason stopped — lack of efficacy, intolerance, contraindication, etc.). 2. Clinical response records — chart notes, lab values, and disease-activity assessments showing how the patient fared on each prior therapy. 3. Intolerance or contraindication documentation — if any required step drug was not tried because of a documented reason, include that clinical justification. 4. Prescriber medical-necessity letter — a specialist letter explicitly addressing the step-therapy sequence, confirming which steps were completed and why the TNF inhibitor is now warranted. 5. Florida Blue's current step-therapy policy — download from floridablue.com to confirm every required step and match each to the documented record.

## Criteria-Mapping Strategy

List each required step from Florida Blue's policy in sequence. For each step, enter the specific therapy tried, the dates of the trial, and the documented outcome. If a step was skipped for a legitimate clinical reason, document that reason explicitly. Attach the relevant chart pages behind each step entry. This structured presentation allows the reviewer to confirm protocol completion without searching through unorganized records, and it preempts common "incomplete step" objections.